BRISTOL-MYERS SQUIBBDL-10/ US1101221083 /
11/11/2024 10:59:50 PM | Chg. +5.580 | Volume | Bid10:59:50 PM | Ask10:59:50 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
55.910EUR | +11.09% | - Turnover: - |
55.910Bid Size: - | 56.130Ask Size: - | 113.86 bill.EUR | - | - |
GlobeNewswire
9/2
CSE Announces its 2024 Sustainability & ESG Leadership Summit at NYC's One World Trade Center
GlobeNewswire
8/30
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
8/28
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising A...
GlobeNewswire
8/22
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...
GlobeNewswire
8/15
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...
GlobeNewswire
8/12
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in C...
Newsfile Corp
8/12
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
GlobeNewswire
8/8
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/7
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Diseas...
GlobeNewswire
8/5
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
GlobeNewswire
8/1
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies i...
GlobeNewswire
8/1
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
7/31
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Boar...
GlobeNewswire
7/25
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
GlobeNewswire
7/24
Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado
GlobeNewswire
7/20
NCLA Asks Third Circuit to Rule Against HHS’s Coercive Medicare Drug Price ‘Negotiation’ Program